Salute e Benessere

Alta Semper acquires Allmed Group to deliver advanced blood purification and…

Alta Semper acquires Allmed Group to deliver advanced blood purification and dialysis solutions worldwide London, UK, 13 thof June 2024;Allmed Group (" Allmed " or "theCompany "), a producer of end-to-end blood purification and haemodialysis solutions, announced today that Alta Semper Capital (“ Alta Semper ”), a London-based private equity firm specialising in impact investments primarily in the healthcare sector across growth markets, has entered into definitive...
Nasdaq GlobeNewswire
13/06/2024

Adrenocortical Carcinoma Market to Exhibit Growth at a CAGR of 11.1% by 2034 |…

Key Takeaways from the Adrenocortical Carcinoma Market Report Key Takeaways from the Adrenocortical Carcinoma Market Report Discover which therapies are expected to grab the major adrenocortical carcinoma market share @Adrenocortical Carcinoma Market Report Adrenocortical Carcinoma Overview Adrenocortical carcinoma is a rare but aggressive cancer originating in the adrenal cortex. The cause of adrenocortical carcinoma is largely unknown, though genetic mutations and...
PR Newswire
12/06/2024

Aesthetic procedures close to 35 million in 2023

Aesthetic Procedures Aesthetic Procedures Liposuction was the most common surgical procedure in 2023 as in 2022, with more than 2.2 million, followed by breast augmentation, eyelid surgery, abdominoplasty, and rhinoplasty. The most popular non-surgical procedures were botulinum toxin, hyaluronic acid, hair removal, non-surgical skin tightening, and non-surgical fat reduction. All face and head procedures showed notable growth from the previous year, with more than 6.5 million...
PR Newswire
12/06/2024

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in…

Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by a single point mutation in theHBBgene, which encodes the β subunit of hemoglobin (Hb). Normally, red blood cells adopt a disc-like shape that allows them to move easily through the blood vessels and deliver oxygen throughout the body. In sickle cell disease, red blood cells become crescent or “sickle”-shaped, a dysfunctional state that impairs blood flow, oxygen delivery and triggers...
Nasdaq GlobeNewswire
12/06/2024

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined…

PARIS and CAMBRIDGE, Mass., June12, 2024(GLOBE NEWSWIRE) -- NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST.The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr...
Nasdaq GlobeNewswire
12/06/2024

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; June 12, 2024 –Genmab A/S(Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date...
Nasdaq GlobeNewswire
12/06/2024

Sanofi: Information concerning the total number of voting rights and shares –…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of 2,529,599,938 € Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
12/06/2024

SAFE - First implantations of the Sycamore device in Switzerland

First implantations of the Sycamore device in SwitzerlandFleurieux-sur-l'Arbresle-France – June 12, 2024 at 6 p.m. Safe SA, announces the first implantations of Sycamore devices by Professor Maestretti, at the cantonal hospital of Friborg in Switzerland. The Sycamore implant is a unique implant that allows minimally invasive operations to treat vertebral compression fractures, improve mobility, restore the height of vertebral bodies and reduce back pain (pedicle anchored kyphoplasty)...
Nasdaq GlobeNewswire
12/06/2024

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and…

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancerby Dr Stephen Liu and Prof Benjamin BesseNANTES, France, June 12, 2024 – 6:00pm CETIn this webinar, OSE Immunotherapeutics joins key opinion leadersDr Stephen Liu, associate professor and director of Thoracic Oncology at Georgetown University Lombardi Comprehensive Cancer Center (Washington DC, United States) andProf Benjamin Besse, medical oncologist...
Nasdaq GlobeNewswire
12/06/2024

Aktiia Receives Regulatory Approval for the World's First Optical Blood Pressure…

The healthcare industry is already taking note: "The ability to monitor blood pressure without using a cuff is a game-changer. This achievement has the potential to greatly improve hypertension care, from better patient motivation to more efficient medication regimens," said Adrian James, former President of Omada Health. The healthcare industry is already taking note: " The ability to monitor blood pressure without using a cuff is a game-changer. This achievement has the…
PR Newswire
12/06/2024

Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking…

Presented recently at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) presented two abstracts related to their novel immunotherapy, pelareorep, an intravenously delivered immunotherapeutic agent. Presented recently at the 2024American Society of Clinical Oncology (ASCO)Annual Meeting,Oncolytics Biotech Inc.(NASDAQ: ONCY) (TSX: ONC)presented two abstractsrelated to their novel immunotherapy, pelareorep, an...
PR Newswire
12/06/2024

Vaccines Market to be Worth $71.50 billion in 2031- Exclusive Report by…

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. Vaccines activate the immune system without making us sick. Many dangerous infectious diseases can be prevented in this simple and effective way. Also, immunization is a way to build our body's natural immunity against disease. The market's growth is driven by the strong pipeline for vaccines, increasing government initiatives toward immunization, and technological advancements in the…
PR Newswire
12/06/2024

Veterinary Ophthalmology Equipment Market Hits $485M in 2024, Anticipates 7.5%…

Browse in-depth TOC on "Veterinary Ophthalmology Equipment Market" Browse in-depth TOC on "Veterinary Ophthalmology Equipment Market" 336 - Tables 66 - Figures 319 - Pages Market Drivers: Rising Pet Ownership and Expenditure The surge in pet ownership, amplified by increasing income levels, demographic shifts, and the impact of the COVID-19 pandemic, is propelling the demand for specialized veterinary services, notably in ophthalmology. This heightened awareness of pet...
PR Newswire
12/06/2024

Avicenna.AI secures FDA clearance for AI detection of vertebral compression…

Often resulting from the deterioration of bone structure (osteoporosis), VCFs can cause significant pain, deformity, and height loss. In the USA, approximately 750,000 adults suffer from osteoporotic VCFs each year, but around two-thirds of those go undetected or unreported. Often resulting from the deterioration of bone structure (osteoporosis), VCFs can cause significant pain, deformity, and height loss. In theUSA, approximately 750,000 adults suffer from osteoporotic VCFs each year, but...
PR Newswire
12/06/2024

Ansell Recognized with the Frost & Sullivan 2024 Global Company of the Year…

Ansell is deeply committed to ensuring the safety and well-being of workers with its highly advanced personal protection equipment and safety solutions. Their customer-centric approach is exemplified through innovative solutions like the Worker Experience Innovation platform and exceptional educational support services such as AnsellCARES. Ansell offers groundbreaking technologies, especially in the form of two significant technologies, ERGOFORM, and PI-KARE, which are designed to protect…
PR Newswire
12/06/2024

ELFBAR and LOST MARY redefine next-gen vaping at World Vape Show 2024

"We can't wait to share our latest R&D results in products with adult users worldwide, including those in the Middle East," said Jacques Xiang Li, spokesperson for ELFBAR and LOST MARY. "We can't wait to share our latest R&D results in products with adult users worldwide, including those in theMiddle East," saidJacques Xiang Li, spokesperson for ELFBAR and LOST MARY. "We've been turbocharging the effort to align products more with the users' cessation journey…
PR Newswire
12/06/2024

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted…

Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors. /2 clinical trial of OBI-992, an antibody-drug conjugate (ADC) targeting TROP2 (Trophoblast cell-surface antigen 2), an antigen overexpressed in multiple tumor types. OBI plans to enroll patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer (GC), and other potential cancers. The objective of the trial is to verify the safety,...
Nasdaq GlobeNewswire
12/06/2024

Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to…

Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO ®in the UK and IrelandLugano, Switzerland – June 12, 2024– Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and Chugai Pharma Europe Ltd (“Chugai”), the European subsidiary of Chugai Pharmaceutical Co, Ltd., one of Japan's leading...
Nasdaq GlobeNewswire
12/06/2024

DoH and Penn Medicine to expand collaboration on translational research and…

Through this MoU, DoH and Penn Medicine seek to design and develop a translational medicine ecosystem based on Penn'sInstitute for Translational Medicine and Therapeutics (ITMAT). In addition, the MoU seeks to explore the potential of launching two multi-year collaborative research programmes. One focuses on the expanded application of artificial intelligence to identify new potential antibiotics. The other focuses on longitudinal follow-up and genetic analysis of people with Alzheimer's in Abu…
PR Newswire
12/06/2024

Senior life science and medical specialists join SmartCella's Board of Directors

At the Annual General Meeting, Anna Martling (Professor of Surgery and Scientific Director Life Science at Karolinska Institutet), Claude Dartiguelongue (previously senior roles with Lonza, Thermo Fisher Scientific and Becton Dickinson and Company), and Regina Fritsche-Danielson (PhD in Cardiovascular Physiology/Pharmacology and Senior Vice President and Global Head of Research and Early Development, Cardiovascular, Renal and Metabolic Diseases at AstraZeneca) were appointed new members of the…
PR Newswire
12/06/2024

TELUS Mental Health Index: 44 per cent of workers feel exhausted after work…

"There is no question that AI's advancement will bring significant benefits, potentially as pivotal as the industrial or internet age," said Paula Allen, Global Leader, Research & Client Insights, TELUS Health. "Organizations have the opportunity to engage employees in this evolution by ensuring that AI tools and training are readily accessible to employees, and enabling them to explore the technology firsthand so they can discover the ways it benefits them in their own work…
PR Newswire
12/06/2024

Insider Information: Nexstim Plc Provides Further Details on Technology License…

Company announcement, Helsinki, 12 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Provides Further Details on Technology License Agreement with Magnus Medical, Inc. Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) announces that it has disagreements regarding the licensing of the Company's technology to medical technology company Magnus Medical, Inc. (”Magnus Medical”). The technology licensed is related to the NBT® system developed by the Company, with certain restrictions,...
Nasdaq GlobeNewswire
12/06/2024

Crossject appoints Dan Chiche, MD as Chief Medical Officer North America

Brings extensive experience in drug development in the U.S and internationally and in maximizing value of medical productsReinforces leadership team and expands presence in North AmericaSupports processes targeting ZEPIZURE® regulatory milestones in the U.S. in 2025Dijon, France 12 June 2024, 7:30 am CET- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the...
Nasdaq GlobeNewswire
12/06/2024

BioSenic to host Annual General Meeting on July 12, 2024

PRESS RELEASE – REGULATED INFORMATIONPreliminary documents for the Annual General Meeting have been made available on company's websiteMont-Saint-Guibert, Belgium, June 12th, 2024 7.00am CET –BioSenic(Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune and inflammatory diseases and cell repair, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the annual...
Nasdaq GlobeNewswire
12/06/2024
Altri  Comunicati